Related Experiment Video
Updated: Jun 3, 2026
08:35
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
Iron and cardiovascular dysfunction: mechanisms and therapeutic implications.
1Assistant Professor of Surgery, Cornell University Medical College, Assistant Attending Surgeon (Vascular), The New York Hospital, New York, New York.
Surgical Technology International
|March 15, 2011
Summary
Tissue hypoperfusion increases plasma iron levels. Iron is released into circulation and tissues following ischemia and reperfusion in organs like the heart, intestines, kidneys, and brain.
Area of Science:
- Biochemistry
- Physiology
- Pathology
Background:
- Tissue hypoperfusion has been linked to elevated plasma iron for over 30 years.
- Iron liberation into circulation is observed following reperfusion of ischemic tissues.
- Previous studies show iron delocalization in postischemic brain, myocardium, and kidney.
Purpose of the Study:
- To investigate the delocalization of iron during skeletal muscle ischemia.
- To determine if iron delocalization persists upon reperfusion in skeletal muscle.
Main Methods:
- Experimental observations of iron levels in plasma and urine.
- Demonstration of iron delocalization in ischemic skeletal muscle.
- Assessment of iron status post-reperfusion.
Main Results:
- Iron is delocalized from skeletal muscle during ischemia.
- This iron delocalization process continues even after reperfusion.
- Confirms iron delocalization in other organs like brain, heart, and kidney.
Conclusions:
- Ischemia and reperfusion lead to significant iron delocalization across multiple organ systems.
- Understanding iron's role in ischemia-reperfusion injury is crucial for therapeutic development.
- Further research into iron chelation therapies may be warranted.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...